Submitted: 22 Jan 2018
Revised: 21 Feb 2018
Accepted: 15 Mar 2018
First published online: 12 Jun 2018
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - FireFox Plugin)

Int J Basic Sci Med. 2018;3(2):89-93.
  Abstract View: 68
  PDF Download: 103

Original article

Adipokine Omentin-1: A Diagnostic Tool in Breast Cancer

Abstract

Background and objective: Breast cancer is one of the leading causes of cancer-related death and the most common solid malignancy in women worldwide. Omentin-1 is produced by visceral adipose tissue, placenta, and ovary that its production is affected by some cancers. The aim of this study was to assess omentin-1 in patients with breast cancer to be applied as a biomarker in the diagnosis of breast cancer. Methods: In this case-control study, 45 patients with breast cancer and 45 healthy women as control group were included. In addition to anthropometric and blood parameters analysis, omentin-1 serum levels were measured by enzyme-linked immunosorbent assays method. Receiver operator characteristic curve and positive and negative predictive values (PPV and NPV) were calculated to define the diagnostic accuracy. Results: Serum omentin-1 level in breast cancer group was significantly lower than the control group. There was no significant correlation between omentin-1 levels and anthropometric and blood parameters analysis. The best cut-off point for the diagnosis of breast cancer was at 146 ng/L. Calculated PPV and NPV based on 66% disease prevalence were 88.8% and 51.5%, respectively. Conclusions: Serum level of omentin-1 was significantly lower than the healthy group, so, it can be used as a screening test along with the early-approved methods in diagnosis of patients with breast cancer in the future.
First name
 
Last name
 
Email address
 
Comments
 
Security code